...

A PHASE Ia/Ib, OPEN LABEL, MULTICENTER, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7502175 AS A SINGLE AGENT AND IN COMBINATION WITH CHECKPOINT INHIBITOR IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

This is a first-in-human study to learn about the investigational drug called RO7502175.

Why this Research Matters

Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Who can Participate

Adult

Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study

Study ID

Protocol Number: 22-1245
More information available at ClinicalTrials.gov: NCT05581004

Meet the Team

Image of Principal Investigator

Antonio Jimeno, MD, PhD

Principal Investigator

Categories

Locations